P2D Bioscience (P2D) is a specialty pharmaceutical company focused on developing innovative drugs for the treatment of central nervous system (CNS) inflammatory disorders including Frontotemporal Dementia (FTD) and Alzheimer’s disease (AD).

At P2D, our experienced drug development team utilizes “Targeted Phenotypic Screening” and transgenic preclinical models of neurodegenerative diseases to accelerate our drug development process. Our goal is to advance a product candidate through preclinical efficacy testing, GLP-safety studies and early clinical safety and clinical proof-of-concept studies then seek partners to complete the clinical development and commercialization process.

P2D currently has a pipeline of drug candidates that are: 1) orally and centrally active isoindoline TNFα inhibitors for the treatment FTD and AD and 2) benztropine-analog DAT inhibitors for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD).